Vermisol

Quick links to important sections

Vermisol

Method of action: Anthelmintic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vermisol

What is Vermisol? (Levamisole)

Vermisol is a synthetic, prescription-only medicinal product whose principal active ingredient is Levamisole, usually formulated as the highly soluble hydrochloride salt. It is classified as a dual-action compound, primarily recognized as an anthelmintic agent, and secondarily as an immunomodulator. This dual capacity is a unique and clinically recognized property supported by pharmacological studies.

Property Description
Active ingredient Levamisole (Levamisole hydrochloride)
Form Oral tablets, Oral solution
Pharmacological class Anthelmintic, Immunomodulator
Common use Elimination of parasitic worms
Origin Synthetic (Imidazothiazole derivative)

What Type of Medicine is Vermisol (Levamisole)?

Vermisol belongs to the pharmacological class of anthelmintics, specifically identified as an Imidazothiazole derivative. This classification defines the drug’s primary general therapeutic purpose: to alleviate the distress and risks associated with parasitic infestations, particularly those caused by roundworms and hookworms. Its distinct secondary classification is that of an immunomodulator, as Levamisole possesses the capacity to potentially restore or enhance depressed T-cell function in the body's immune response. This indicates the medicine has an effect both on eliminating parasites and supporting the body's defense mechanisms.


Composition, Origin, and Available Forms

The active substance, Levamisole, is a synthetic compound entirely manufactured chemically, ensuring consistent purity and potency. It is the pharmacologically active levo-enantiomer purified from the predecessor compound, Tetramisole. The Vermisol preparation is generally available as oral tablets or an oral solution, with administration being through the oral route. Being a single active ingredient product (monotherapy), its high-level composition includes Levamisole hydrochloride alongside standard pharmaceutical excipients necessary for formulating stable solid or liquid dosage forms.


What is the General Therapeutic Purpose of Vermisol?

The general therapeutic purpose of Vermisol is rooted in its highly efficient, paralyzing action against parasitic organisms, coupled with its potential to support the body’s defenses. Levamisole works by rapidly overstimulating the nerve and muscle systems of the worms, leading to immediate paralysis and facilitating their subsequent natural elimination from the gastrointestinal tract. The medicine is indicated for the treatment of human infections by various types of intestinal worms. Separately, the immunomodulatory action of Levamisole aims to support or normalize a compromised immune system in specific clinical contexts.

Regulatory References

  1. [PubChem-Levamisole]
  2. [NIH-Immune-Effects]
  3. [WHO-Essential-Medicines]
  4. dual-action compound
  5. anthelmintic
  6. Imidazothiazole derivative

What side effects are possible with Vermisol?

Possible side effects and safety information

The officially documented safety profile of Vermisol (Levamisole) is organized by regulatory authorities to classify potential adverse reactions based on their frequency and the body system affected. These classifications are defined by data collected from clinical use, distinguishing between commonly observed effects and those that are rare but serious.

Adverse Reaction Classification

Classification Examples of Documented Effects
Common Gastrointestinal disturbances (such as nausea, vomiting, abdominal pain, and diarrhea), Headache.
Uncommon Dizziness, fatigue, skin rash, pruritus (itching).
Rare Agranulocytosis, Encephalopathy, Seizures, and serious cutaneous reactions.

Adverse reactions are grouped into System-Organ Classes (SOCs) including Gastrointestinal Disorders, Nervous System Disorders, and Blood and Lymphatic System Disorders. The latter category is critical, as official prescribing information highlights the potential for serious hematological toxicity, notably Agranulocytosis, which is a rare but severe reduction in white blood cells. This effect may manifest several weeks or months following treatment initiation, establishing a duration-related safety pattern documented in regulatory texts.

Safety Constraints and Considerations

Official labeling imposes high-level safety restrictions. The medicine is generally constrained from use in individuals with pre-existing Blood Dyscrasias (disorders of the blood), particularly those affecting white blood cell counts. Furthermore, the label defines a safety necessity for regular hematological monitoring during the course of treatment to observe for the onset of such blood disorders. Caution is also advised for patients with existing Hepatic Impairment due to the risk of liver enzyme elevation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Vermisol (Levamisole) based on documented systemic manifestations and mandatory emergency actions. Acute overdose may present with documented gastrointestinal symptoms, including nausea, vomiting, diarrhea, and abdominal pain. Central Nervous System (CNS) manifestations such as dizziness, confusion, headache, and lethargy are also officially noted in regulatory labeling.

More severe manifestations documented in official sources include seizures (convulsions), profound neurotoxicity, respiratory depression, and potential circulatory collapse. Due to the risk of severe and life-threatening outcomes, regulatory guidance mandates that in the event of an overdose or the development of escalating symptoms, individuals must seek medical advice immediately and contact emergency services or a national Poison Control Center for immediate assessment.

The regulatory-defined management strategy is strictly symptomatic and supportive treatment, as official labeling confirms that no specific antidote is known for Levamisole overdose. Procedural measures like gastric lavage or activated charcoal may be considered in a supervised medical setting, alongside continuous monitoring of vital functions, especially due to the potential for CNS and respiratory compromise.

Therapeutic Uses of Vermisol

What Vermisol Treats: Main Uses and Benefits

Vermisol is commonly used to provide supportive relief across key symptom-focused domains, primarily addressing discomfort associated with acute or episodic changes and contributes to easing the overall symptom load experienced by the patient. The product is applied within the framework of symptomatic treatment.

The medicine is relevant in contexts marked by increased discomfort or tension, applied across domains where additional symptomatic support is needed. It helps address groups of symptoms that may appear suddenly or fluctuate, addressing symptoms that create noticeable physiological strain and are used in situations involving recurrent or episodic manifestations. In clinical settings that involve acute or unstable symptom patterns, the application is focused on supportive symptom management. Vermisol may assist with easing temporary functional strain and supports general well-being during symptomatic phases.


Quick Fact: Relevant for Managing Symptoms that Interfere with Daily Functioning

Regulatory References

  1. European Medicines Agency

Eligibility and Restrictions for Use

The eligibility profile for Vermisol (Levamisole) strictly outlines the populations authorized for use by regulatory authorities, distinguishing between those permitted, those requiring caution, and those who must not use the medicine.

Eligibility Status Patient Group and Rule
Allowed Adults and Children are the established age groups for use in authorized regions.
Absolute Contraindication Individuals with a known hypersensitivity to the drug or any pre-existing blood disorders must not use Vermisol.
Conditional Use Patients with liver disease (hepatic impairment) require caution and close monitoring, and use is generally not recommended for those with severe kidney disease (renal impairment).

Official labeling generally states that use during pregnancy and lactation is not recommended and may be formally contraindicated by some national health authorities. Regulatory caution is also advised for patients with specific comorbid conditions like rheumatoid arthritis or epilepsy. The medicine is subject to regional restrictions; for example, it is no longer available for human use in the U.S. market, which restricts eligibility within that jurisdiction.

What should I know about interactions with other medicines?

The official interaction profile for Vermisol (Levamisole) is defined by mandatory restrictions and documented exposure-altering effects, based strictly on government regulatory labeling.

Formal Restrictions and Prohibitions

Co-administration with certain substances is restricted due to formally recognized risks. Treatment with organophosphorus compounds is prohibited within a 14-day separation window before or after Levamisole administration. The label restricts the simultaneous use of lipophilic preparations (such as chloroform or ether) due to the potential to increase the medicine’s toxicity.

Consumption of alcohol (ethanol) is prohibited during treatment and for at least 24 hours following intake, as this co-administration is documented to produce a disulfiram-like reaction. Simultaneous use of antihistamine-containing products is also officially restricted.

Exposure-Modifying Effects

Levamisole is documented to impact the regulatory profile of certain co-administered medicines. It increases the plasma concentration of phenytoin. For coumarin-type anticoagulants (like Warfarin), co-administration can result in a prolongation of prothrombin time, reflecting an officially increased anticoagulant effect. The profile documents changes in the bioavailability of other anthelmintic agents such as Albendazole and Ivermectin. These documented constraints communicate the necessary, label-based administration requirements.

Mechanism of Action

How Vermisol Works: Pharmacodynamic Mechanism

Vermisol (Levamisole) functions via a dual pharmacological mechanism, engaging two distinct biological systems: the neuromuscular system of susceptible parasites and the host's immune pathways.


Parasite Neuromuscular System Overstimulation

This mechanism involves the selective agonism of Nicotinic Acetylcholine Receptors ( nAChRs) located on the somatic muscle cells of the target parasite. This interaction forces a sustained opening of cation channels, inducing continuous muscle depolarization. The resultant irreversible spastic paralysis is a key physiological consequence, causing the worm to lose muscular control and allowing clearance by host peristaltic activity.


Modulation of Host Immune Cell Signaling

The second domain is the modulation of host immune pathways, primarily targeting depressed T-lymphocyte ( CD4^+ and CD8^+) and phagocyte functions. By influencing key cellular signaling pathways, Levamisole modifies cellular activity within these immune cells. This results in the modulation of function of cell-mediated immunity, a resultant physiological effect which is contingent on the functional state of the immune system.

Dosage and Administration Information

Official Administration Guidelines

The official use of Vermisol (Levamisole) is governed by specific administration parameters that strictly define the route, dosage, and frequency, depending on the approved context of use.


Administration Scope

Instruction Category Official Guideline
Route of administration Administration is limited to the oral route, utilizing the available tablet or solution formulations.
Dosing schedule The standard dosing pattern exhibits duality. For the acute use, the regimen is a single dose of 150 mg in adults. For the cyclic use, the dose is 50 mg three times daily for three consecutive days.
Timing in relation to meals The medicine is officially sanctioned to be administered with or without food.
Age-group administration rules The standard pediatric regimen requires the dose to be calculated by body weight at 2.5 mg/kg for a single treatment course in children under 12 years.
Special procedural conditions In cases where acute infection is persistent, retreatment with the single dose may be considered and administered after a minimum of seven days.

Instruction Classifications (High-Level)

Classification Description
Administration method type Oral (Tablets and Solution).
Frequency pattern Single-use (acute) or Intermittent Cyclic (long-term).
Regulatory basis Based on established clinical and pharmaceutical parameters.
Use-context constraints Use is constrained by duration (one day vs. up to one year) and the need for weight-based calculation in pediatric populations.

Resulting Procedural Structure

The official instructions establish two distinct procedural protocols based on the application, defining strict parameters for the amount and the duration. These standardized parameters mandate the oral route and require specific weight-based dose calculation for children, structuring the standardized use of the medicine across all regulated contexts.

Recent Clinical Evidence

Evidence for Vermisol's Primary Action: Treating Parasitic Worm Infections

The primary research base for Vermisol concerns its classification as an anthelmintic agent. Randomized Controlled Trials (RCTs) and field investigation studies were the main designs used in research exploring how symptoms change over time related to parasitic infestations. These studies, conducted in both adults and children, primarily monitored outcomes such as measured parasite clearance and the change in the number of eggs present in the feces. The evidence base for this purpose is categorized as High-level data by reviewing bodies. However, research is limited by a lack of modern comparative evidence against newer alternatives and limited information for long-term outcomes beyond the immediate clearance of the infection.


Research on Vermisol's Immunomodulatory Role in Chronic Conditions

Research explored the dual action of Vermisol by studying its characteristics in specific chronic conditions, examining outcomes related to systemic or functional imbalance.

Studies Focused on Nephrotic Syndrome in Children

Studies were conducted in pediatric cohorts (children) using RCTs that monitored outcomes like the frequency of relapse and the duration of remission status. The overall evidence supporting this use is generally described as Moderate. Certainty remains low in some reviews because many trials had modest sample sizes and demonstrated heterogeneity in protocols.

Research on Adjuvant Therapy for Colon Carcinoma

Historical, large-scale clinical trials (including RCTs) monitored overall patient survival and recurrence rates over a period of years. The research contributes to understanding long-term outcomes, but these studies are historical and focused strictly on the drug used in combination therapy with a specific chemotherapy agent, meaning the results apply only to the populations studied under those specific conditions.


Remaining Research Gaps and Areas of Uncertainty

Research has examined the persistence of measured changes, but long-term effects are not fully established. Data for certain groups, such as older adults or pregnancy-related populations, remain insufficient. Furthermore, the findings describe group patterns, not personal outcomes, and the research provides context but not individual predictions.

Key Studies & References

  1. Levamisole - Electronic Essential Medicines List (EML)

Frequently Asked Questions (FAQ)

Common questions about Vermisol (FAQ)

Q: How quickly should I expect Vermisol to start working?

A: Official product information notes that the medicine acts to paralyze the target organisms. Official information suggests that the primary therapeutic effect may occur within 24 hours. This rapid effect supports the intended purpose of the medication.

Q: Does Vermisol work for everyone who takes it?

A: Studies and official information indicate that all medicines are tested on groups of patients, and the findings describe the expected pattern of response. Individual biological factors may influence the outcome. It is important to understand that regulatory data describes group outcomes and cannot predict a specific individual result or response.

Q: Are there any foods or drinks I need to avoid while using Vermisol?

A: Official product labeling strictly prohibits the consumption of alcohol during treatment with this medicine. While the use of the medicine with food is generally addressed as part of its administration, any specific dietary modifications are best addressed by a healthcare professional.

Q: Can older people (seniors) use Vermisol?

A: Regulatory documents state that this medicine has been used in older adult patients. While specific clinical trials may not always compare outcomes in the elderly versus younger adults, available information does not suggest that its use would cause different side effects or problems than it does in younger adults.

Q: What should I do if I think I'm experiencing a severe reaction to Vermisol?

A: If an individual suspects a serious reaction, it is necessary to seek emergency medical attention immediately. Symptoms that require urgent attention include high fever, chills, unusual bleeding, or significant swelling.

Q: Are there any long-term consequences of using Vermisol?

A: The official safety profile documents the potential for rare, serious, long-term complications with this medicine. These have included blood disorders, such as agranulocytosis (a severe drop in white blood cells), and nervous system disorders like leukoencephalopathy.

Q: Why does Vermisol need a prescription?

A: Vermisol is classified as a prescription-only medicinal product due to the potential for serious adverse effects. This classification is in place to ensure medical supervision and monitoring are in effect during use.

Q: What does 'contraindication' mean regarding Vermisol?

A: In regulatory terms, a contraindication means the medicine must not be used in a specific patient group or situation. This rule is established because official medical authorities have determined that the risk associated with its use in that context outweighs any potential benefit.

Q: What is the risk of a serious interaction with other medicines?

A: The official product label documents several major interactions with other medicines, indicating a significant risk. These interactions include effects on certain blood thinners, which can be highly clinically significant. These prohibited or restricted combinations are factors to discuss with a prescriber.

Q: Can Vermisol affect my ability to drive or operate machinery?

A: Official labeling indicates that side effects like drowsiness or dizziness have been reported. Official labeling states that individuals should understand how the medicine affects them before engaging in activities like driving or operating heavy machinery.

Q: What are the inactive ingredients in Vermisol?

A: The official product monograph includes a list of inactive ingredients, also called excipients, used in the formulation. These substances vary by the specific product but commonly include standard ingredients like starch, magnesium stearate, and other stabilizing agents necessary for the tablets or solution.

Q: Does Vermisol come in different strengths?

A: The medicine is generally available in different tablet strengths for oral use. Official formularies typically document the existence of 50 mg and 150 mg tablet preparations, which allows for different prescribed dosing schedules.

Q: Is the 'how it works' section in the leaflet complicated?

A: The regulatory documents require that the mechanism of action be explained using precise scientific terms, which can be technical. However, the essential effect is that the medicine acts to paralyze the target worms, allowing the body’s natural processes to eliminate them from the system.

Q: Why is it important to know about drug interactions with Vermisol?

A: It is important to know about drug interactions because using Vermisol with certain other products can significantly alter the outcome. The official product monograph documents that interactions may either increase the risk of serious side effects or change how effective one or both medicines are.

Q: How long after stopping Vermisol can I safely use it again?

A: Official administration guidelines include a specific protocol for retreatment for persistent acute infection. This protocol states that a subsequent single dose may be considered and administered after a minimum of seven days. General instructions for re-starting treatment after a planned cessation are subject to specific medical guidance.

Q: Do I need any special tests before starting Vermisol?

A: Official prescribing information recommends that patients undergo specific tests before starting treatment and periodically throughout the course. This monitoring commonly includes blood tests (such as a complete blood count) and liver function tests to observe the body's response to the medicine.

Q: How is the safety profile of Vermisol generally described?

A: The safety profile is described as encompassing both mild, common side effects and the potential for rare but serious adverse effects. Due to the possibility of serious outcomes, such as blood disorders or neurological problems, official guidance emphasizes the importance of regular medical monitoring.

Q: What is a 'drug interaction' in the context of Vermisol?

A: A drug interaction is a high-level description for when one medicine changes the way another medicine works in the body. In the context of Vermisol, interactions may cause side effects to become worse, or they may make the treatment less effective.

Q: Does Vermisol interact with vitamins or supplements?

A: The official labeling may not list every possible vitamin or supplement interaction. Official safety advice states that all other medications, supplements, and herbal products must be discussed with a healthcare professional.

Q: What kind of pain relievers, like ibuprofen, can interact with Vermisol?

A: Official drug interaction screeners have identified acetaminophen (paracetamol) as a possible minor or moderate interaction. Any questions regarding the use of specific pain relievers must be addressed by the prescribing clinician.

Q: What happens if I forget to use Vermisol as instructed?

A: Official guidance for a missed dose is to skip it and resume the regular dosing schedule. Patients are specifically advised not to double the next dose. If a dose is missed, instructions for the next steps must be obtained from a healthcare professional.

Q: Is it okay to stop using Vermisol if I feel better?

A: According to the official administration guidelines, all treatment should be completed as prescribed. Patients should only discontinue use on the advice of their care team to ensure the proper treatment course is followed.

Q: How long does Vermisol stay in your system?

A: Official pharmacological data indicate that the medicine is rapidly absorbed and metabolized by the body. The rate at which the active substance is eliminated from the bloodstream is described by a short plasma elimination half-life of 3–4 hours.

Q: Is Vermisol a federally controlled substance?

A: The active ingredient, Levamisole, is not classified as a federally controlled substance in the United States. However, it is important to note that a subsequent metabolite of the active ingredient is currently listed as a Schedule I substance.

Q: Is Vermisol known to cause mood changes or depression?

A: The list of documented side effects includes irritability as a possible effect on the nervous system. Patients experiencing any unwanted mood changes must consult with their healthcare professional.

Q: Does Vermisol affect blood pressure or heart rate?

A: The adverse reaction profile includes reports of effects on the cardiovascular system. Specifically, official documents mention a possible fast heartbeat (tachycardia) or a rapid, pounding, or irregular heartbeat.

How should Vermisol be stored and disposed of?

How to Store and Dispose of Vermisol?

This section outlines the official regulatory requirements for the storage and disposal of this medicine, based on government-issued labeling standards (e.g., FDA, Health Canada, EMA).

Storage Requirements

Requirement Official Statement
Temperature & Environment Store at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F).
Protection Keep the container tightly closed and store the medicine in its original packaging to protect from moisture.
Safety The product must be stored out of the sight and reach of children and pets.

Disposal Instructions

Official disposal guidelines mandate securing the product to prevent misuse and protecting the environment:

  • Take-Back Programs: The primary method for disposal is through an approved drug take-back program or mail-back service, if available.
  • Household Disposal: If no take-back option is available, unused medicine should be mixed with an unappealing substance (like dirt or coffee grounds), sealed in a plastic bag, and placed into the household trash.
  • Environmental Protection: The medicine must not be flushed down the toilet or poured into a drain unless it is specifically identified on the FDA flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vermisol found in:

A-Z Index: